Trial Profile
Phase 2 study of AMV564 in patients with acute myeloid leukemia (AML)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Vixtimotamab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Aug 2016 New trial record